Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 18,635 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult Clear all
Recruiting Phase 2 Interventional

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

NCT07230288
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
ABBV-142, Placebo for ABBV-142
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Birmingham, Alabama • Dothan, Alabama • Kissimmee, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 25, 2026, 11:41 AM EDT
Active, not recruiting Not applicable Interventional

Video-based Intervention to Address Disparities in Blood Pressure Control After Stroke

NCT05264298
View directory record Official record
Conditions
Stroke
Interventions
VIRTUAL, Standard care
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 25, 2026, 11:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

NCT02270463
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Tagraxofusp-erzs
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Tampa, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 25, 2026, 11:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Category Learning Retention in Adults With and Without Developmental Language Disorder

NCT05901493
View directory record Official record
Conditions
Developmental Language Disorder, Adults Without Language Disorder
Interventions
Perceptual category training
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 55 Years
Enrollment
540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Newark, Delaware • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 25, 2026, 11:41 AM EDT
Not listed Phase 2 Interventional

Rosiglitazone Effects on Cognition for Adults in Later Life

NCT00242593
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Rosiglitazone
Drug
Lead sponsor
University of Washington
Other
Eligibility
55 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Phoenix, Arizona • Los Angeles, California • Seattle/Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 4 Interventional

HPV Educational Intervention to Increase Acceptance and Completion of Free HPV Vaccination Among Underserved Adults

NCT04474821
View directory record Official record
Conditions
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Interventions
Educational Intervention, Survey Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

NCT03475706
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
86
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 25, 2026, 11:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

NCT07594106
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Goodyear, Arizona • Duarte, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 1 Interventional

A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight

NCT07605052
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Cagrilintide B, Cagrilintide D
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine

NCT01402947
View directory record Official record
Conditions
Healthy
Interventions
Ciprofloxacin XR + MMX Placebo, MMX Mesalazine/mesalamine + Ciprofloxacin XR
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)

NCT06597760
View directory record Official record
Conditions
Healthy
Interventions
Enlicitide, Digoxin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw

NCT01646060
View directory record Official record
Conditions
Blood Loss, Healthy
Interventions
CM-1500
Device
Lead sponsor
Zynex Monitoring Solutions
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 25, 2026, 11:41 AM EDT
Terminated Phase 2 Interventional

A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

NCT04897880
View directory record Official record
Conditions
Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor, Malignant Rhabdoid Tumor, Recurrent Brain Tumor, Childhood
Interventions
Panobinostat
Drug
Lead sponsor
Australian & New Zealand Children's Haematology/Oncology Group
Other
Eligibility
Up to 39 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 2 Interventional

506U78 in Treating Patients With Lymphoma

NCT00005080
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Small Intestine Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome
Interventions
nelarabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 69 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 25, 2026, 11:41 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.

NCT04739696
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Colon Cancer, Solid Tumor, Adult
Interventions
PEPRR, Pep-Pal
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 64 Years
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 3 Interventional Results available

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

NCT02889796
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
48
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs

NCT00920088
View directory record Official record
Conditions
Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions
darunavir/ritonavir, lopinavir/ritonavir, Midazolam, Dextromethorphan, Flurbiprofen, GSK2248761
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Oct 25, 2026, 11:41 AM EDT
Recruiting Not applicable Interventional

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome

NCT05535361
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome
Device
Lead sponsor
Eclipse Regenesis, Inc.
Other
Eligibility
3 Months to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 25, 2026, 11:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the Reproducibility of Jumping Mechanography

NCT01164670
View directory record Official record
Conditions
Sarcopenia
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
70 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)

NCT02781480
View directory record Official record
Conditions
Leber Congenital Amaurosis
Interventions
AAV RPE65
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 25, 2026, 11:41 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

NCT07422480
View directory record Official record
Conditions
Myelodysplastic Syndrome, Anemia
Interventions
Elritercept, Epoetin Alfa
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
31
States / cities
Gilbert, Arizona • Duarte, California • Santa Rosa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

NCT03340662
View directory record Official record
Conditions
Healthy Volunteer
Interventions
CC-122, Itraconazole, Fluvoxamine, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 25, 2026, 11:41 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults

NCT06863142
View directory record Official record
Conditions
Influenza Prevention, Seasonal Influenza
Interventions
VRC-FLUMOS0116-00-VP, ALFQ
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 11:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Lidocaine in Healthy Adults

NCT03310970
View directory record Official record
Conditions
Healthy
Interventions
Lidocaine 5% patch, Lidocaine hydrochloride, Lidoderm 5% patch
Drug
Lead sponsor
Nicole K Brogden
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 25, 2026, 11:41 AM EDT